Teleflex (TFX) Earnings Date & Reports

Key Takeaways

• Teleflex reported third-quarter revenue from continuing operations of $567.8 million, up 0.2% year over year on a reported basis and 3.0% on a pro forma adjusted constant-currency basis.
• Adjusted diluted earnings per share (EPS) from continuing operations rose to $2.63, up 39.2% from $1.89 in the prior-year period and ahead of management's expectations.
• GAAP (Generally Accepted Accounting Principles) diluted EPS from continuing operations was $1.30, compared with a loss of $1.32 a year earlier.
• Vascular and Surgical delivered solid growth, while the Interventional segment returned to modest growth as integration of the acquired Vascular Intervention business progressed.
• Teleflex raised its full-year 2026 adjusted diluted EPS guidance to a range of $7.50 to $7.75 while maintaining its pro forma adjusted constant-currency revenue growth outlook of 3.5% to 4.5%.
• The company repurchased approximately $350 million of common stock during the period, with $400 million remaining under its $1 billion authorization.
• For more on this ticker's Major News, Today's Price Move, Price Targets, and Forecast, be sure to explore the dedicated pages.
• Discover automated market ideas by exploring Trending AI Robots.

Earnings Context and Why It Matters

Teleflex is in the middle of a portfolio-wide transformation, and this quarter offered investors a clearer read on how that effort is translating into financial results. The company has divested its OEM (original equipment manufacturer) business and is working to close the sale of its Acute Care and Interventional Urology units, while simultaneously integrating the Vascular Intervention business acquired from BIOTRONIK. Against that backdrop, the third-quarter report matters less for headline growth than for evidence that margins are expanding, earnings power is improving, and the remaining businesses can sustain procedure-driven demand. With management framing 2026 as a transition year, these results help establish whether the simplified, more focused Teleflex is on track for the earnings step-up it has promised in 2027.

Reported Results

For the third quarter ended September 30, 2026, Teleflex posted revenue from continuing operations of $567.8 million, a 0.2% reported increase and a 3.0% rise on a pro forma adjusted constant-currency basis. Adjusted diluted EPS from continuing operations reached $2.63, up 39.2% from $1.89 a year earlier, while GAAP diluted EPS was $1.30 versus a prior-year loss of $1.32.

By segment, Vascular generated $243.5 million (up 4.6% on a constant-currency basis), Surgical contributed $114.0 million (up 5.1%), and Interventional produced $210.3 million, returning to modest growth of 0.2% as integration activities progressed. Adjusted gross margin expanded to 66.8%, aided in part by a $25.3 million benefit from IEEPA (International Emergency Economic Powers Act) tariff refunds, and adjusted operating margin rose to 25%.

Teleflex increased its full-year 2026 adjusted diluted EPS guidance to $7.50 to $7.75 and raised its GAAP EPS outlook to $2.84 to $3.09, while maintaining its constant-currency revenue growth guidance of 3.5% to 4.5%.

AI Screener

Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener can help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors monitoring medical-device names like Teleflex alongside broader market moves, the AI Screener offers a practical way to surface actionable ideas quickly.

Market Reaction and Investor Sentiment

Sentiment heading into the print centered on whether Teleflex could demonstrate tangible progress on its transformation, particularly in the Interventional business and on margin expansion. The results delivered on both fronts: adjusted EPS rose sharply, adjusted operating margin expanded, and management raised its full-year earnings outlook. The one notable wrinkle was GAAP EPS of $1.30, which fell slightly short of the consensus estimate of $1.32, though adjusted EPS of $2.63 far exceeded expectations and reflects the company's emphasis on non-GAAP performance measures. Investors also weighed the company's continued confidence in closing the Acute Care and Interventional Urology divestiture, even as regulatory timing could extend into 2027.

Forward Outlook and Key Factors to Monitor

Looking ahead, Teleflex's guidance raise points to improving earnings momentum, but execution risk remains the central theme. The most important near-term catalyst is the completion of the Acute Care and Interventional Urology divestiture to Intersurgical, which management expects to close by year-end subject to regulatory review. A delay into 2027 would push back the associated capital-allocation benefits and the streamlined operating model the company is building.

Investors should also track the Interventional segment's trajectory. Management has noted progress on customer conversions, distributor transitions, and sales-force territory openings, but sustained improvement will require continued integration execution. Meanwhile, capital returns are an ongoing focus: Teleflex has signaled roughly $1 billion in share repurchases and $800 million in debt reduction tied to divestiture proceeds.

Finally, longer-term growth platforms deserve attention. EZPLAZ, the first and only FDA-licensed freeze-dried plasma, represents a potential U.S. market opportunity of at least $200 million, while Freesolve, a resorbable magnesium scaffold, recently received FDA Breakthrough Device Designation for PCI (percutaneous coronary intervention, a procedure to open narrowed arteries). These programs are unlikely to move near-term results materially but could shape the company's growth profile over the coming years.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations